Panel Examines Discovery, Manufacture, Delivery of COVID-19 Vaccine

The Johns Hopkins Carey Business School recently hosted a virtual panel discussion

that examined aspects of COVID-19 vaccine, from discovery to manufacturing to delivery.

Bloomberg Distinguished Professor of Health Policy and Economics Daniel Polsky of the Carey Business School led the discussion.

It featured the comments of Carey alumnus Bill Enright (MS, Business Management ’96), chief executive officer of Vaccitech, the biotechnology company that has teamed with Oxford University and AstraZeneca on the development, manufacture, and distribution of a COVID-19 vaccine; Abigail Jenkins, senior vice president and vaccine business unit head for Emergent BioSolutions, the Maryland-based biopharmaceutical company that develops vaccines and antibody therapeutics; and Reed Tuckson, managing director of Tuckson Health Connections and former public health commissioner for Washington, D.C.

“The reality of this situation is that the number of emerging and infectious diseases is increasing – or at least the identification of those emerging and infectious diseases is increasing – over the last 80 years,” Enright noted, adding, “So this isn’t a one-and-done. It’s a continuing problem that’s going to face us.”

The January 25, 2021, event was the latest entry in Carey’s Distinguished Speaker Series.

The video of the full presentation can be viewed at https://www.youtube.com/watch?v=MJcaIkZJ7oc.

Besides his affiliation with the Carey Business School, Polsky serves on the faculty of the Johns Hopkins Bloomberg School of Public Health. He also is the director of the Hopkins Business of Health Initiative, whose mission is “advancing the health of the nation and its communities through a U.S. health system driven by value, affordability, and equity.”